Patient Guide: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 38 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT04077723
Status: 🟢 Enrolling Now
Condition: Lymphoma, Non-Hodgkin
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 38 locations across the country.

Top locations include:
  • • Pasadena, California
  • • San Francisco, California
  • • Denver, Colorado
  • • And 35 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma - Join Clinical Trial NCTNCT04077723

How to Join This Clinical Trial - NCTNCT04077723

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Lymphoma, Non-Hodgkin. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Lymphoma, Non-Hodgkin. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Lymphoma, Non-Hodgkin
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT04077723 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 38 locations. Find a study site near you:

Clinical Research Site

Pasadena, California 91105 - United States

Status: ACTIVE_NOT_RECRUITING

Clinical Research Site

San Francisco, California 94158 - United States

Status: RECRUITING

Clinical Research Site

Denver, Colorado 80218 - United States

Status: RECRUITING

Clinical Research Site

Boston, Massachusetts 02215 - United States

Status: RECRUITING

Clinical Research Site

Saint Louis, Missouri 63110 - United States

Status: RECRUITING

Clinical Research Site

Houston, Texas 77030-4009 - United States

Status: RECRUITING

Clinical Research Site

Melbourne, Victoria 3000 - Australia

Status: RECRUITING

Clinical Research Site

Melbourne, Victoria 3004 - Australia

Status: RECRUITING

Clinical Research Site

Gent, 9000 - Belgium

Status: RECRUITING

Clinical Research Site

Halifax, Nova Scotia B3H 2Y9 - Canada

Status: RECRUITING

And 28 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Lymphoma, Non-Hodgkin:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships